Status:
COMPLETED
A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions
Lead Sponsor:
Boehringer Ingelheim
Conditions:
HIV Infections
Hepatic Insufficiency
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The objective of this study was to evaluate the steady-state clearance of nevirapine among HIV-1 positive patients with hepatic fibrosis, and to examine whether the degree of hepatic impairment influe...
Eligibility Criteria
Inclusion
- INCLUSION
- Male or female subjects \>=18 years of age with HIV-1 infection and chronic liver disease as reflected by a documented biopsy with hepatic fibrosis present.
- a. Participants must be receiving nevirapine 200 mg twice daily as part of a stable ARV regimen for a minimum of 6 weeks prior to trough level sample collection.
- b. Participants receiving nevirapine 400 mg once daily as part of a stable ARV regimen for a minimum of 6 weeks, who are willing to switch to nevirapi0 mg twice daily for a minimum of 14 days prior to trough collection.
- Participants must have uoxylin and Eosin (H and E) stained slide and one trichrome stained pathology slide available at the time of enrollment. There is no time restriction on liver biopsy slides that pathologically confirm the presence of cirrhosis. The presence of cirrhosis must be documented on the liver biopsy report.
- EXCLUSION
- Current (within the past 4 weeks) HIV antiviral therapy with other NNRTI's.
- Concurrent use (within the past 7 days) of any of the following:
- Systemic azole antifungal agents (fluconazole, itraconazole, ketoconazole, etc.)
- Clarithromycin
- Rifampin
- St John's Wort
- Inability to provide a blood sample.
- Patients who have evidence for hepatic or other encephalopathy above Grade 1
- Patients with renal failure who require dialysis.
- Pregnant and/or breast feeding women..
Exclusion
Key Trial Info
Start Date :
June 25 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00144248
Start Date
June 25 2004
Last Update
December 1 2023
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site
Bakersfield, California, United States
2
Boehringer Ingelheim Investigational Site
San Francisco, California, United States
3
California Pacific Medical Center
San Francisco, California, United States
4
Albany Medical College, MC 142
Albany, New York, United States